Aptose Biosciences IncTSX:APSView on NASDAQ
- LAST PRICE0.2500
- TODAY'S CHANGE (%)-0.0900 (-26.4706%)
- Bid / Lots0.2550/ 8
- Ask / Lots0.2650/ 10
- Open / Previous Close0.2350 / 0.3400
- Day Range
- 52 Week Range
- Volume335,751
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APS |
|---|---|---|
| 09:32 ET | 12500 | 0.205 |
| 09:33 ET | 8000 | 0.205 |
| 09:37 ET | 5000 | 0.2 |
| 09:39 ET | 59000 | 0.205 |
| 09:42 ET | 3000 | 0.2 |
| 09:44 ET | 1000 | 0.2 |
| 09:46 ET | 500 | 0.2 |
| 09:48 ET | 1000 | 0.2 |
| 09:51 ET | 6000 | 0.195 |
| 09:53 ET | 500 | 0.195 |
| 09:55 ET | 3500 | 0.2 |
| 09:57 ET | 1500 | 0.195 |
| 10:00 ET | 4000 | 0.195 |
| 10:08 ET | 31000 | 0.195 |
| 10:09 ET | 6500 | 0.195 |
| 10:22 ET | 5500 | 0.195 |
| 10:26 ET | 3000 | 0.195 |
| 10:27 ET | 3000 | 0.195 |
| 10:31 ET | 3500 | 0.195 |
| 10:33 ET | 4500 | 0.195 |
| 10:45 ET | 5000 | 0.2 |
| 10:49 ET | 13500 | 0.2 |
| 10:54 ET | 7000 | 0.2 |
| 10:56 ET | 2500 | 0.2 |
| 11:12 ET | 5500 | 0.195 |
| 11:16 ET | 3000 | 0.2 |
| 11:18 ET | 1000 | 0.2 |
| 11:25 ET | 12500 | 0.2 |
| 11:30 ET | 2500 | 0.2 |
| 11:34 ET | 11500 | 0.2 |
| 11:38 ET | 1000 | 0.195 |
| 12:03 ET | 500 | 0.21 |
| 12:08 ET | 2000 | 0.225 |
| 12:10 ET | 10500 | 0.22 |
| 12:12 ET | 3000 | 0.235 |
| 12:28 ET | 500 | 0.23 |
| 12:30 ET | 6000 | 0.22 |
| 12:32 ET | 4500 | 0.215 |
| 12:39 ET | 500 | 0.22 |
| 12:46 ET | 6000 | 0.22 |
| 12:51 ET | 6500 | 0.23 |
| 01:00 ET | 1000 | 0.225 |
| 01:06 ET | 2500 | 0.23 |
| 02:07 ET | 54500 | 0.22 |
| 02:36 ET | 500 | 0.24 |
| 03:10 ET | 1000 | 0.23 |
| 03:12 ET | 5000 | 0.245 |
| 03:44 ET | 3000 | 0.25 |
Today
Nov 20, 2024
DJ Aptose Biosciences Is Maintained at Buy by HC Wainwright & Co., from 1:11PM ET on Wednesday Nov 20, 2024 by Dow Jones
1:11PM ET on Wednesday Nov 20, 2024 by Dow JonesAptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy, from 7:30AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:30AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 8, 2024
*DJ Aptose Biosciences 3Q Loss/Shr 37c >APTO, from 4:01PM ET on Friday Nov 08, 2024 by Dow Jones
4:01PM ET on Friday Nov 08, 2024 by Dow JonesAptose Reports Results for the Third Quarter 2024, from 4:01PM ET on Friday Nov 08, 2024 by Dow Jones
4:01PM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aptose Biosciences Inc | 4.4M | 0.0x | --- |
Company Information
Aptose Biosciences Inc. is a clinical-stage biotechnology company engaged in developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Contact Information
- Headquarters
- 251 Consumers Rd Suite 1105NORTH YORK, ON, Canada M2J 4R3
- Phone
- 647-479-9828
- Fax
- 416-798-2200
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 18.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.14 |
EPS | $-3.06 |
Book Value | $-0.37 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
